Corvus director awarded 15,000 stock options
Corvus Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 15,000 shares of Common Stock.
Rhea-AI Filing Summary
Corvus Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $11.6000 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or the date of Corvus’ 2027 annual stockholders’ meeting, assuming continuous board service through that date. Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, any securities or economic benefits from these options are to be provided to OrbiMed Private Investments V, LP, and Thompson disclaims beneficial ownership except to any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,000 shares
Grant/Award
1 txn
Insider
Thompson Peter A.
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,000 contracts (Direct)
Footnotes (2)
- F1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
- F2. Pursuant to an agreement with OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Option grant size: 15,000 options
Exercise price: $11.6000 per share
Expiration date: June 11, 2036
+2 more
5 metrics
Option grant size
15,000 options
Stock Option (Right to Buy) granted on June 11, 2026
Exercise price
$11.6000 per share
Conversion or exercise price of the stock options
Expiration date
June 11, 2036
Option expiration for the 15,000-share grant
Shares underlying options
15,000 shares
Underlying Common Stock covered by the options
Derivative position after grant
15,000 options
Total derivative securities following this transaction
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, beneficial ownership, pecuniary interest, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
beneficial ownership financial
"the Reporting Person disclaims beneficial ownership of the securities reported herein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
derivative securities financial
"this report shall not be deemed an admission that the Reporting Person is a beneficial owner of the derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
What did the Corvus Pharmaceuticals (CRVS) director report on this Form 4?
The filing shows director Peter A. Thompson was granted stock options on 15,000 Corvus Pharmaceuticals Common Stock shares. These options are a compensation award, not an open-market share purchase or sale, and are reported as a derivative security transaction.
What are the key terms of the Corvus (CRVS) stock options granted?
The options cover 15,000 shares of Corvus Common Stock at an exercise price of $11.6000 per share. They expire on June 11, 2036, providing a long-dated right to buy shares at that fixed price if they ultimately vest.
How do the Corvus (CRVS) options granted to the director vest?
The options vest 100% on the earlier of the first anniversary of the grant date or the 2027 annual stockholders’ meeting. Vesting is conditional on the director maintaining continuous service on the Corvus board through the applicable vesting date.
Who ultimately benefits from the Corvus (CRVS) options reported on this Form 4?
Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, any securities or economic benefits from these options are transferred for the benefit of OrbiMed Private Investments V, LP. Thompson disclaims beneficial ownership except for any pecuniary interest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
